Clearside Biomedical Inc. (CLSD)
Clearside Biomedical Statistics
Share Statistics
Clearside Biomedical has 77.28M shares outstanding. The number of shares has increased by 1.49% in one year.
Shares Outstanding | 77.28M |
Shares Change (YoY) | 1.49% |
Shares Change (QoQ) | 0% |
Owned by Institutions (%) | 12.63% |
Shares Floating | 61.02M |
Failed to Deliver (FTD) Shares | 2.89K |
FTD / Avg. Volume | 1.37% |
Short Selling Information
The latest short interest is 468.9K, so 0.62% of the outstanding shares have been sold short.
Short Interest | 468.9K |
Short % of Shares Out | 0.62% |
Short % of Float | 0.66% |
Short Ratio (days to cover) | 2.61 |
Valuation Ratios
The PE ratio is -2.04 and the forward PE ratio is -1.48. Clearside Biomedical's PEG ratio is 0.18.
PE Ratio | -2.04 |
Forward PE | -1.48 |
PS Ratio | 42.14 |
Forward PS | 0.6 |
PB Ratio | -1.8 |
P/FCF Ratio | -2.84 |
PEG Ratio | 0.18 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Clearside Biomedical.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.44, with a Debt / Equity ratio of -0.02.
Current Ratio | 4.44 |
Quick Ratio | 4.44 |
Debt / Equity | -0.02 |
Debt / EBITDA | -0.03 |
Debt / FCF | -0.03 |
Interest Coverage | -2.95 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $52K |
Profits Per Employee | $-1.07M |
Employee Count | 32 |
Asset Turnover | 0.07 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -41.61% in the last 52 weeks. The beta is 2.04, so Clearside Biomedical's price volatility has been higher than the market average.
Beta | 2.04 |
52-Week Price Change | -41.61% |
50-Day Moving Average | 0.92 |
200-Day Moving Average | 1.05 |
Relative Strength Index (RSI) | 40.87 |
Average Volume (20 Days) | 211.29K |
Income Statement
In the last 12 months, Clearside Biomedical had revenue of 1.66M and earned -34.35M in profits. Earnings per share was -0.47.
Revenue | 1.66M |
Gross Profit | 1.51M |
Operating Income | -28.88M |
Net Income | -34.35M |
EBITDA | -24.35M |
EBIT | -24.57M |
Earnings Per Share (EPS) | -0.47 |
Balance Sheet
The company has 20.02M in cash and 703K in debt, giving a net cash position of 19.32M.
Cash & Cash Equivalents | 20.02M |
Total Debt | 703K |
Net Cash | 19.32M |
Retained Earnings | -355.27M |
Total Assets | 25.13M |
Working Capital | 16.48M |
Cash Flow
In the last 12 months, operating cash flow was -24.7M and capital expenditures 0, giving a free cash flow of -24.7M.
Operating Cash Flow | -24.7M |
Capital Expenditures | 0 |
Free Cash Flow | -24.7M |
FCF Per Share | -0.33 |
Margins
Gross margin is 91.05%, with operating and profit margins of -1735.7% and -2064.42%.
Gross Margin | 91.05% |
Operating Margin | -1735.7% |
Pretax Margin | -2064.42% |
Profit Margin | -2064.42% |
EBITDA Margin | -1463.16% |
EBIT Margin | -1735.7% |
FCF Margin | -1484.25% |
Dividends & Yields
CLSD does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for CLSD is $5, which is 525% higher than the current price. The consensus rating is "Buy".
Price Target | $5 |
Price Target Difference | 525% |
Analyst Consensus | Buy |
Analyst Count | 5 |
Scores
Altman Z-Score | -21.55 |
Piotroski F-Score | 3 |